Phase 1/2Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors

Sponsor
AskGene Pharma, Inc. (Industry)
Enrollment
594 planned
Conditions
Advanced Solid Tumors
Interventions
ASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
Ages
adults, older adults
Registry
NCT05867420

Full record on ClinicalTrials.gov

From the registry

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

Primary outcomes

  • Dose limiting toxicities (DLTs)
  • Adverse events(AEs)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered